UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 441

Sortiert nach

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis

Hepatology (Baltimore, Md.), 2021-11, Vol.74 (5), p.2452-2466

2021

Volltextzugriff (PDF)

Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production

Gastroenterology (New York, N.Y. 1943), 2021-04, Vol.160 (5), p.1741-1754.e16

2021

Volltextzugriff (PDF)

The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery

Journal of gastroenterology, 2022-02, Vol.57 (2), p.111-119

2022

Volltextzugriff (PDF)

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma

Hepatology research, 2022-07, Vol.52 (7), p.630-640

2022

Volltextzugriff (PDF)

CTGF Mediates Tumor-Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Cancer research (Chicago, Ill.), 2018-09, Vol.78 (17), p.4902-4914

2018

Volltextzugriff (PDF)

Prevalence of 25 canine behavioral problems and relevant factors of each behavior in Japan

Journal of Veterinary Medical Science, 2019, Vol.81(8), pp.1090-1096

2019

Volltextzugriff (PDF)

Prevalence of 17 feline behavioral problems and relevant factors of each behavior in Japan

Journal of Veterinary Medical Science, 2020, Vol.82(3), pp.272-278

2020

Volltextzugriff (PDF)

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy

Hepatology research, 2022-03, Vol.52 (3), p.298-307

2022

Volltextzugriff (PDF)

Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis

Internal Medicine, 2021/03/01, Vol.60(5), pp.745-750

2021

Volltextzugriff (PDF)

Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway

Scientific reports, 2020-01, Vol.10 (1), p.941-941, Article 941

2020

Volltextzugriff (PDF)

Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation

The Journal of clinical investigation, 2021-07, Vol.131 (13), p.1-14

2021

Volltextzugriff (PDF)

Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients

PloS one, 2022-07, Vol.17 (7), p.e0271020-e0271020

2022

Volltextzugriff (PDF)

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy

Cancers, 2022-02, Vol.14 (4), p.883

2022

Volltextzugriff (PDF)

Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination

Alimentary pharmacology & therapeutics, 2022-02, Vol.55 (4), p.422-433

2022

Volltextzugriff (PDF)

Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma

Hepatology research, 2020-03, Vol.50 (3), p.365-373

2020

Volltextzugriff (PDF)

Hepatocellular Carcinoma in a Patient with Tetralogy of Fallot: A Case Report and Literature Review

Internal Medicine, 2022/05/01, Vol.61(9), pp.1361-1365

2022

Volltextzugriff (PDF)

The First Transileocolic Obliteration for Refractory Esophageal Varices: A Case Report and Review of the Literature

Internal Medicine, 2022/03/15, Vol.61(6), pp.835-839

2022

Volltextzugriff (PDF)

Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma

Hepatology research, 2020-11, Vol.50 (11), p.1275-1283

2020

Volltextzugriff (PDF)

Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller

Digestive diseases and sciences, 2022-12, Vol.67 (12), p.5704-5711

2022

Volltextzugriff (PDF)

Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation

Scientific reports, 2020-09, Vol.10 (1), p.15290, Article 15290

2020

Volltextzugriff (PDF)

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection

PloS one, 2020-06, Vol.15 (6), p.e0234811-e0234811

2020

Volltextzugriff (PDF)

1 – 25 von 441

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(360)
Mit Volltextzugriff
(426)

Publikationsform

Sprache

Englisch
(387)
Japanisch
(181)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Transcriptomics Identify Thrombospondin‐2 as a Biomarker for NASH and Advanced Liver Fibrosis

Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production

The absence of warfarin treatment and situs inversus are associated with the occurrence of hepatocellular carcinoma after Fontan surgery

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma

CTGF Mediates Tumor-Stroma Interactions between Hepatoma Cells and Hepatic Stellate Cells to Accelerate HCC Progression

Prevalence of 25 canine behavioral problems and relevant factors of each behavior in Japan

Prevalence of 17 feline behavioral problems and relevant factors of each behavior in Japan

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy

Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis

Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

Dysregulation of PI3K and Hippo signaling pathways synergistically induces chronic pancreatitis via CTGF upregulation

Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy

Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination

Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma

Hepatocellular Carcinoma in a Patient with Tetralogy of Fallot: A Case Report and Literature Review

The First Transileocolic Obliteration for Refractory Esophageal Varices: A Case Report and Review of the Literature

Initial treatment response to transarterial chemoembolization as a predictive factor for Child–Pugh class deterioration prior to refractoriness in hepatocellular carcinoma

Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2 cm or Smaller

Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection

Suchergebnisse filtern